I thank the gentleman. I appreciate being one of the eulogists for Mike Oxley. I am going to go at this a little bit differently than the other speakers. I am going to talk about Mike Oxley as the baseball player and manager of the…

We all agree that it is important for FDA to get it right, but most of us think it is also time for FDA to get on down the road.

It looks to me like we have two issues here. We have an FDA issue, you are right, seeing Ms. Woodcock.

I cannot overstate the importance of treating each biosimilar individually rather than as if they were a generic drug.

This approach undermines the real intent of the legislation.

I wish that Congresswoman Eshoo was a member of the subcommittee because, while I know a little bit about this, Anna is really the expert on this issue.

Six years ago, I co-authored, along with Congresswoman Anna Eshoo, the Biologics Price Competition and Innovation Act.

Mr. Speaker, the first thing that I want to do is commend the gentleman from North Dakota for his hard work on this. He is an original cosponsor of H.R. 702. He is a valued member of the ad hoc whip team that we put together. He and I have…

Thank you for your leadership. I am going to have to excuse myself, but thank you for this Special Order.

We have a fleet of privately owned ships that are normally in private commercial operation and that are owned by the companies that operate here in the ports of the United States. We pay a small fee each year from the Department of Defense…

I feel like I am stuck in a Dickens novel. It is the best of times, it is the worst of times.